prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype LumA, Not for Permanent Storage in Medical Records / Not Valid for Signing. Date of Service. Performing Facility. Result Provider. Report Name. Surgical Report. SEE REPORT. ADDENDUM INFORMATION. PROCEDURE DATE. ADDENDUM REPORT #2; COMMENT: The panel of breast cancer markers was performed at. using material from block B/BPC3. The results are summarized in part B/BPC. line 10. I have seen the results and concur with the findings as stated. T: ADDENDUM REPORT #2: DIAGNOSIS: A/APC & C. SEE ORIGINAL DIAGNOSES. B/BPC. RIGHT BREAST MASS, EXCISTON: 1 - 9. SEE ORIGINAL DIAGNOSES. 10. ANCILLARY STUDIES: BREAST CANCER PROGNOSTIC PANEL: ASSAY RESULTS. Staining. Percent. Test Name. Intensity. Positive. Prognostic. Assay Type. Average. Average. Significance. ER. N/A. 37%. Favorable. PR. N/A. 71%. Favorable. HER-2/neu. 1.7. N/A. Normal Limit. Ki-67. N/A. 18%. Borderline. REFERENCE RANGES. Test. Favorable. Borderline. Unfavorable. ER. <5%. >5%. Her2/neu. <2.0. >2.0. Ki-67. <10%. >10% - <20%. >20%. 11. SEE ORIGINAL DIAGNOSIS. A-MALIGNANT. T: ADDENDUM REPORT #1;. ENT: An immunostain for E-cadherin utilizing material from block A is entirely. negative. This supports the light microscopic diagnosis of lobular carcinoma. ADDENDUM REPORT #1; DIAGNOSIS: PENDING BREAST CANCER PANEL STUDIES ON 8/BPC-3. A & APC. SENTINEL LYMPH NODE. RIGHT AXILLA: METASTATIC LOBULAR CARCINOMA. Not for Permanent Storage in Medical Records / Not Valid for Signing. Date of Service. Performing Facility. Result Provider. Report Name. Surgical Report. PRESENT IN ONE LYMPH NODE ; NEGATIVE E.-CADHERIN IMMUNOSTAIN. B & BPC. RIGHT BREAST MASS. EXCISION: 1. TUMOR TYPE: INFILTRATING LOBULAR CARC1NOMA, SEE COMMENT. BELOW. 2 - 11. SEE ORIGINAL DIAGNOSES. C. SEE ORIGINAL DIAGNOSIS. COMMENT: As noted. breast cancer marker studies will be performed on B/BPC-3. A-MALIGNANT. (Electronic Signature). PROCEDURE DATE: SPECIMEN DESCRIPTION: A. RIGH AXILLARY SENTINEL LYMPH NODE, APC. B. RIGHT BREAST BIOPSY, BPC. C. AXILLARY CONTENTS. PRE-OPERATIVE - DIAGNOSIS: Right breast cancer. POST-OPERATIVE DIAGNOSIS: Same. CLINICAL INFORMATION: Invasive ductal carcinoma in retroareolar space; right breast mass. INTRAOPERATIVE CONSULTATION: APC DIAGNOSIS: "Metastatic carcinoma, by Dr. BPC DIAGNOSIS: "Tissue obtained for genomics, by. T: GROSS DESCRIPTION: A. Received in formalin is an irregular tan-gray nodule, measuring 2.0 X 1.6. X 0.5 cm. The specimen is bisected and entirely submitted in one cassette. APC. Received in formalin is an irregular portion of tan-gray soft tissue,. measuring 1.5 X 1.5 X 0.2 cm. The specimen is entirely submitted in one. cassette. B/BPC. Received in formalin is a portion of tan-yellow fibrofatty tissue,. measuring 6.8 cm from medial to lateral, 6.7 cm from superior to inferior. and. 4.8 cm from anterior to posterior. The specimen is orrented as follows: short. stitch - superior: long stitch - lateral. The anterior aspect is covered by. skin, measuring 5.0 X 3.0 X 0.2 cm. Centrally located on the skin surface is. the nipple, measuring 1.0 X 1.0 X 0.8 cm. The cut surface of the nipple is. tan and unremarkable. The specimen is inked as follows: superior - blue;. inferior - green; medial - red: lateral - yellow; anterior - orange: posterior. black. Sectioning from medial to lateral reveals a poorly-defined tan-gray. Not for Permanent Storage in Medical Records / Not Valid for Signing. Date of Service. Performing Facility. Result Provider. Report Name. Surgical Report. tumor mass, measuring approximately 5.0 X 3.0 X 1.5 cm. This area is. diffusely covered with blue radiographic dye. The cut surface is firm and. gritty. The tumor mass blends into the adjacent thick fibrotic tissue. The. tumor comes to within 1.0 cm of the medial margin. 0.2 cm of the lateral. margin. 2.0 cm of the superior margin, 0.7 cm of the inferior margin. 1.5 cm. of the skin and nipple, and abuts the posterior margin. The reinaining cut. surface is composed of approximately 50% adipose tissue and 50% fibrous. tissue. A biopsy cavity or metallic clip is not found. Representative. sections are sequentially submitted, from medial to lateral. in six cassettes. as follows: cassette 1 - medial margin; cassette 2 - nipple with anterior. aspect: cassette 3 - tumor mass with closest posterior margin; cassette 4 -. tumor mass with superior margin; cassette 5 - tumor mass with inferior margin;. cassette 6 - tumor mass with lateral margin. C. Received in formalin is an irregular portion of tan-yellow fatty tissue. measuring 5 X 4 x 2 cm. Six possible lymph nodes. ranging from 0.4 X 0.3 x. 0.3 cm to 1.5 x 1.0 X 0.8 cm, are identified. The cut surface of the largest. lymph node shows foci of tan-gray discoloration. The lymph nodes are entirely. submitted in four cassettes as follows cassette 1 - one intact and one. bisected lymph node; cassette 2 - one lymph node: cassette 3 - two bisected. lymph nodes (one inked black): cassette 4 - largest lymph node. MICROSCOPIC DESCRIPTION: A & APC. One slide is examined for each portion of the case. Both slides. demonstrate extensive lymph node involvement by poorly differentiated. carcinoma. Because of the obvious nature of this finding, it will not be. necessary to perform a cytokeratin stain. B/BPC. Six slides are examined. Slide 1 show benign breast tissue without. evidence of tumor involvement. The red inked medial margin is free of. tumor. Slide 2 shows tissue from the region of the nipple. There is patchy. ductal hyperplasia and no evidence of Paget's disease is evident. Slide 3. shows extensive infiltrating carcinoma with a pattern most suggestive of. lobular carcinoma with periductal targetoid-lik areas and numerous foci of. "Indian file" arrangement. On this slide, tumor is present approximately 0.1. mm to the black inked posterior surface. The tumor shows no evidence of. tubular formation (tubules = 3). Nuclei exhibit occasional prominent nucleoli. and these seem to be multiple in some scattered foci. In the most mitotically. active areas of tumor, approximately eighteen to nineteen mitoses are present. within ten high power field (mitoses = 2). The Nottingham score of this. lesion is therefore 7 (3+3+2). making this a grade II lesion. Slide 4 shows. no evidence of malignancy. Slide 5 shows infiltrating carcinoma with a clear. inferior green inked margin. Changes consistent with a prior biopsy site dre. also present. No tumor is seen on slide 6. C. Four slides are examined. These show six lymph nodes. Positive lymph. Not for Permanent Slorage in Medical Records / Not Valid for Signing. Date of Service. Performing Facility. Result Provider. Report Name. Surgical Report. nodes are present on C1 and C3 for a total of two positive Tymph nodes out of. six. Including the sentinel Tymph node in part A/APC, a total of three out of. seven lymph nodes are positive for metastatic carcinoma. FINAL DIAGNOSIS: (PRELIMINARY - PENDING BREAST CANCER PANEL STUDIES TO BE PERFORMED ON. B/BPC-3). A & APC. SENTINEL LYMPH NODE, RIGHT AXILLA: METASTATIC CARCINOMA PRESENT IN. ONE LYMPH NODE (1/1). B/BPC. RIGHT BREAST MASS. EXCISION: 1. TUMOR TYPE: INFILTRATING CARCINOMA MOST LIKELY LOBULAR<". CARCINOMA, SEL COMMENT BELOW. 2. NOTTINGHAM PROGNOSTIC INDEX: 7 (3+2+2). GRADE II. 3. MAXIMUM INVASIVE TUMOR SIZE: GROSSLY ESTIMATED AT. APPROXIMATELY 5 CM (pT2). 4. PERCENT DCIS: ZERO. 5. LVI: NOT IDENTIFIED. 6. DISTANCE TO CLOSEST MARGIN: APPROXIMATELY 0.1 MM TO POSTERIOR. INKED MARGIN (B/BPC-3 SLIDE). 7. MICROCALCIFICATIONS: NOT IDENTIFIED. 8. LYMPH NODES: SEE PART C BELOW. 9. TNM STATUS: pT2,N1.MX. 10. ANCILLARY STUDIES: TO FOLLOW ON BLOCK B/BPC-3. 11. OTHER FINDINGS: SEE REPORI. PROCEDURE DATE. =====. FINAL DIAGNOSIS: CHANGES CONSISTENT WITH PRIOR BIOPSY. FOCAL FIBROCYSTIC CHANGES OF REMAINING BREAST PARENCHYMA. C. AXILLARY CONTENTS. RIGHT: METASTATIC CARCINOMA IDENTIFIED IN TWO OF. SIX AXILLARY LYMPH NODES. TOTAL 3/7 INCLUDING SENTINEL LYMPH NODE. AS. ABOVE. COMMENT: As noted. breast cancer marker studies will be performed on B/BPC-3;. in addition to confirm the lobular nature of this tumor, I will order an. E-Cadherin immunostain on block A. A-MALIGNANT. DATE AND TIME OF REPORT:

expanded version (tokens=2650) : 
 Based on the provided pathology report, the following information can be extracted:

1. Histological classification: Infiltrating carcinoma, most likely lobular carcinoma, with extensive lymph node involvement by poorly differentiated carcinoma.
2. Subtype: Luminal-A (based on the results of breast cancer prognostic panel assay results).
3. Necrosis: Not mentioned.
4. Tumor infiltrating lymphocytes: Not identified (LVI not identified).
5. Histological grade: Grade II as per Nottingham Prognostic Index (3+2+2).
6. Nuclear grade: Not mentioned.
7. Lymphovascular invasion: Not identified.
8. Calcification: Not identified.
9. Receptor status: ER-positive (37%), PR-positive (71%), HER-2/neu normal limit (1.7), Ki-67 borderline (18%).
10. IHC and ancillary testing results: E-Cadherin immunostain is negative, pending breast cancer panel studies on block B/BPC-3.

It is important to note that this report is not valid for permanent storage in medical records or for signing, indicating that further investigation or consultation may be required before reaching a definitive diagnosis.

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=2791) : 
 Histological classification of an invasive lobular carcinoma with extensive lymph node involvement by poorly differentiated carcinoma. Luminal-A subtype confirmed (ER-positive and PR-positive, HER-2/neu normal limit, Ki-67 borderline). Grade II as per Nottingham Prognostic Index. E-Cadherin immunostain is negative. No mention of necrosis, tumor-infiltrating lymphocytes, lymphovascular invasion, or calcification. Ancillary testing pending.

